{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:26:45Z","timestamp":1790717205809,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12325-025-03299-0","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T14:14:56Z","timestamp":1757340896000},"page":"5830-5844","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9546-1664","authenticated-orcid":false,"given":"Cristina","family":"Arriens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9507-3338","authenticated-orcid":false,"given":"Eric F.","family":"Morand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4597-5023","authenticated-orcid":false,"given":"Anca D.","family":"Askanase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6712-1585","authenticated-orcid":false,"given":"Richard","family":"Furie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6438-8663","authenticated-orcid":false,"given":"Ronald F.","family":"van Vollenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2096-7023","authenticated-orcid":false,"given":"Kevin","family":"Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0314-5693","authenticated-orcid":false,"given":"Monica","family":"Davey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5930-2767","authenticated-orcid":false,"given":"Kimberly","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2609-7974","authenticated-orcid":false,"given":"Giovanni","family":"Franchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9321-9338","authenticated-orcid":false,"given":"Vaishali","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4860-7509","authenticated-orcid":false,"given":"Carolina Leite","family":"de Oliveria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5935-7997","authenticated-orcid":false,"given":"Coburn","family":"Hobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"3299_CR1","first-page":"330","volume":"6","author":"M Cojocaru","year":"2011","unstructured":"Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Manifestations of systemic lupus erythematosus. Maedica (Bucur). 2011;6:330\u20136.","journal-title":"Maedica (Bucur)"},{"key":"3299_CR2","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1093\/rheumatology\/keh624","volume":"44","author":"DA Isenberg","year":"2005","unstructured":"Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group\u2019s disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005;44:902\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"3299_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83:15\u201329.","journal-title":"Ann Rheum Dis"},{"key":"3299_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001074","volume":"10","author":"HZ Jin","year":"2023","unstructured":"Jin HZ, Li YJ, Wang X, et al. Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study. Lupus Sci Med. 2023;10:e001074.","journal-title":"Lupus Sci Med"},{"key":"3299_CR5","doi-asserted-by":"publisher","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","volume":"11","author":"JR Burke","year":"2019","unstructured":"Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11:eaaw1736.","journal-title":"Sci Transl Med."},{"key":"3299_CR6","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.3389\/fimmu.2019.02590","volume":"10","author":"D Gotthardt","year":"2019","unstructured":"Gotthardt D, Trifinopoulos J, Sexl V, Putz EM. JAK\/STAT cytokine signaling at the crossroad of NK cell development and maturation. Front Immunol. 2019;10:2590.","journal-title":"Front Immunol"},{"key":"3299_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cyto.2018.03.041","volume":"118","author":"HM Hammar\u00e9n","year":"2019","unstructured":"Hammar\u00e9n HM, Virtanen AT, Raivola J, Silvennoinen O. The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine. 2019;118:48\u201363.","journal-title":"Cytokine"},{"key":"3299_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16:843\u201362.","journal-title":"Nat Rev Drug Discov"},{"key":"3299_CR9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13:234\u201343.","journal-title":"Nat Rev Rheumatol"},{"key":"3299_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41584-021-00606-1","volume":"17","author":"RR Goel","year":"2021","unstructured":"Goel RR, Kotenko SV, Kaplan MJ. Interferon lambda in inflammation and autoimmune rheumatic diseases. Nat Rev Rheumatol. 2021;17:349\u201362.","journal-title":"Nat Rev Rheumatol"},{"key":"3299_CR11","unstructured":"European Medicines Agency. SOTYKTU\u2122 (deucravacitinib) summary of product characteristics [Internet]. 2023 [2024 July 3]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sotyktu-epar-product-information_en.pdf. Accessed July 3, 2024."},{"key":"3299_CR12","unstructured":"US Food and Drug Administration. SOTYKTU\u2122 (deucravacitinib) prescribing information [Internet]. 2022 [2024 July 3]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214958s000lbl.pdf. Accessed July 3, 2024."},{"key":"3299_CR13","unstructured":"Bristol Myers Squibb. SOTYKTU\u2122 (deucravacitinib) product monograph [Internet]. 2022 [2024 July 3]. Available from: https:\/\/www.bms.com\/assets\/bms\/ca\/documents\/productmonograph\/SOTYKTU_EN_PM.pdf. Accessed July 3, 2024."},{"key":"3299_CR14","unstructured":"Therapeutic Goods Administration. SOTYKTU\u2122 (deucravacitinib) Australian product information [Internet]. 2022 [2024 July 3]. Available from: https:\/\/www.tga.gov.au\/sites\/default\/files\/2023-09\/auspar-sotyktu-230830-pi.pdf. Accessed July 3, 2024."},{"key":"3299_CR15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.42391","volume":"75","author":"E Morand","year":"2023","unstructured":"Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2023;75:242\u201352.","journal-title":"Arthritis Rheumatol"},{"key":"3299_CR16","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","volume":"81","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Deodhar AA, van der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022;81:815\u201322.","journal-title":"Ann Rheum Dis"},{"key":"3299_CR17","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","volume":"379","author":"K Papp","year":"2018","unstructured":"Papp K, Gordon K, Tha\u00e7i D, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379:1313\u201321.","journal-title":"N Engl J Med"},{"key":"3299_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, Tha\u00e7i D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88:40\u201351.","journal-title":"J Am Acad Dermatol"},{"key":"3299_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000258","volume":"5","author":"JT Merrill","year":"2018","unstructured":"Merrill JT, Manzi S, Aranow C, et al. Lupus community panel proposals for optimising clinical trials: 2018. Lupus Sci Med. 2018;5:e000258.","journal-title":"Lupus Sci Med"},{"key":"3299_CR20","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","volume":"71","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71:1400\u201312.","journal-title":"Arthritis Rheumatol"},{"key":"3299_CR21","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/art.24698","volume":"61","author":"RA Furie","year":"2009","unstructured":"Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61:1143\u201351.","journal-title":"Arthritis Rheum"},{"key":"3299_CR22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","volume":"73","author":"DJ Wallace","year":"2014","unstructured":"Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014;73:183\u201390.","journal-title":"Ann Rheum Dis"},{"issue":"33\u201351","key":"3299_CR23","first-page":"vii","volume":"36","author":"RS Klein","year":"2010","unstructured":"Klein RS, Morganroth PA, Werth VP. Cutaneous lupus and the cutaneous lupus erythematosus disease area and severity index instrument. Rheum Dis Clin North Am. 2010;36(33\u201351):vii.","journal-title":"Rheum Dis Clin North Am"},{"key":"3299_CR24","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","volume":"75","author":"K Franklyn","year":"2016","unstructured":"Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016;75:1615\u201321.","journal-title":"Ann Rheum Dis"},{"key":"3299_CR25","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918\u201330.","journal-title":"Arthritis Rheum"},{"key":"3299_CR26","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1:e208\u201319.","journal-title":"Lancet Rheumatol"},{"key":"3299_CR27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211\u201321.","journal-title":"N Engl J Med"},{"key":"3299_CR28","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1177\/0961203316652492","volume":"25","author":"MA Mahieu","year":"2016","unstructured":"Mahieu MA, Strand V, Simon LS, Lipsky PE, Ramsey-Goldman R. A critical review of clinical trials in systemic lupus erythematosus. Lupus. 2016;25:1122\u201340.","journal-title":"Lupus"},{"key":"3299_CR29","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222\u201333.","journal-title":"Arthritis Rheum"},{"key":"3299_CR30","doi-asserted-by":"publisher","first-page":"e595","DOI":"10.1016\/S2665-9913(21)00119-3","volume":"3","author":"K Connelly","year":"2021","unstructured":"Connelly K, Golder V, Kandane-Rathnayake R, Morand EF. Clinician-reported outcome measures in lupus trials: a problem worth solving. Lancet Rheumatol. 2021;3:e595-603.","journal-title":"Lancet Rheumatol"},{"key":"3299_CR31","unstructured":"US Food and Drug Administration. BENLYSTA (belimumab) prescribing information [Internet]. 2018 [2024 August 27]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125370s062%2C761043s002lbl.pdf. Accessed Aug 27, 2024."},{"key":"3299_CR32","unstructured":"European Medicines Agency. BENLYSTA (belimumab) summary of product characteristics [Internet]. 2017 [2024 August 27]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/benlysta-epar-product-information_en.pdf. Accessed Aug 27, 2024."},{"key":"3299_CR33","unstructured":"GSK. BENLYSTA (belimumab) product monograph [Internet]. 2025 [2024 August 27]. Available from: https:\/\/ca.gsk.com\/media\/6151\/benlysta.pdf. Accessed Aug 27, 2024."},{"key":"3299_CR34","unstructured":"US Food and Drug Administration. SAPHNELO (anifrolumab-fnia) prescribing information [Internet]. 2021 [2024 August 27]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761123s000lbl.pdf. Accessed Aug 27, 2024."},{"key":"3299_CR35","unstructured":"European Medicines Agency. SAPHNELO (anifrolumab-fnia) summary of product characteristics [Internet]. 2024 [2024 August 27]. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2022\/20220214154608\/anx_154608_en.pdf. Accessed Aug 27, 2024."},{"key":"3299_CR36","unstructured":"Therapeutic Goods Administration. SAPHNELO (anifrolumab-fnia) product information [Internet]. 2022 [2024 August 27]. Available from: https:\/\/www.tga.gov.au\/sites\/default\/files\/2022-12\/auspar-saphnelo-221206-pi.pdf. Accessed Aug 27, 2024."},{"key":"3299_CR37","unstructured":"AstraZeneca. SAPHNELO (anifrolumab-fnia) product monograph [Internet]. 2024 [2024 August 27]. Available from: https:\/\/www.astrazeneca.ca\/content\/dam\/az-ca\/downloads\/productinformation\/saphnelo-product-monograph-en.pdf. Accessed Aug 27, 2024."},{"key":"3299_CR38","doi-asserted-by":"publisher","first-page":"1217147","DOI":"10.3389\/fmed.2023.1217147","volume":"10","author":"D Nikolopoulos","year":"2023","unstructured":"Nikolopoulos D, Parodis I. Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition. Front Med (Lausanne). 2023;10:1217147.","journal-title":"Front Med (Lausanne)"},{"key":"3299_CR39","doi-asserted-by":"publisher","first-page":"16021","DOI":"10.1038\/ncomms16021","volume":"8","author":"CD Langefeld","year":"2017","unstructured":"Langefeld CD, Ainsworth HC, Cunninghame Graham DS, et al. Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun. 2017;8:16021.","journal-title":"Nat Commun"},{"key":"3299_CR40","doi-asserted-by":"publisher","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","volume":"62","author":"ST Wrobleski","year":"2019","unstructured":"Wrobleski ST, Moslin R, Lin S, et al. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem. 2019;62:8973\u201395.","journal-title":"J Med Chem"},{"key":"3299_CR41","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","volume":"11","author":"A Chimalakonda","year":"2021","unstructured":"Chimalakonda A, Burke J, Cheng L, et al. Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with janus kinase 1\/2\/3 inhibitors. Dermatol Ther (Heidelb). 2021;11:1763\u201376.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"3299_CR42","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40257-022-00720-0","volume":"23","author":"AM Le","year":"2022","unstructured":"Le AM, Puig L, Torres T. Deucravacitinib for the treatment of psoriatic disease. Am J Clin Dermatol. 2022;23:813\u201322.","journal-title":"Am J Clin Dermatol"},{"key":"3299_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103440","volume":"22","author":"L Ma","year":"2023","unstructured":"Ma L, Peng L, Zhao J, et al. Efficacy and safety of Janus kinase inhibitors in systemic and cutaneous lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2023;22:103440.","journal-title":"Autoimmun Rev"},{"key":"3299_CR44","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","volume":"401","author":"EF Morand","year":"2023","unstructured":"Morand EF, Vital EM, Petri M, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet. 2023;401:1001\u201310.","journal-title":"Lancet"},{"key":"3299_CR45","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","volume":"401","author":"M Petri","year":"2023","unstructured":"Petri M, Bruce IN, Dorner T, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet. 2023;401:1011\u20139.","journal-title":"Lancet"},{"key":"3299_CR46","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/365083","volume":"2010","author":"DY Yap","year":"2010","unstructured":"Yap DY, Lai KN. Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. J Biomed Biotechnol. 2010;2010:365083.","journal-title":"J Biomed Biotechnol"},{"key":"3299_CR47","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.3390\/ijms24043391","volume":"24","author":"L Rusi\u00f1ol","year":"2023","unstructured":"Rusi\u00f1ol L, Puig L. Tyk2 targeting in immune-mediated inflammatory diseases. Int J Mol Sci. 2023;24:3391.","journal-title":"Int J Mol Sci"},{"key":"3299_CR48","doi-asserted-by":"publisher","first-page":"14413","DOI":"10.3390\/ijms241914413","volume":"24","author":"P Richter","year":"2023","unstructured":"Richter P, Macovei LA, Mihai IR, Cardoneanu A, Burlui MA, Rezus E. Cytokines in systemic lupus erythematosus-focus on TNF-alpha and IL-17. Int J Mol Sci. 2023;24:14413.","journal-title":"Int J Mol Sci"},{"key":"3299_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000270","volume":"6","author":"L Ronnblom","year":"2019","unstructured":"Ronnblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med. 2019;6: e000270.","journal-title":"Lupus Sci Med"},{"key":"3299_CR50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13075-019-1878-y","volume":"21","author":"V Oke","year":"2019","unstructured":"Oke V, Gunnarsson I, Dorschner J, et al. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther. 2019;21:107.","journal-title":"Arthritis Res Ther"},{"key":"3299_CR51","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/1535370218824547","volume":"244","author":"M Larosa","year":"2019","unstructured":"Larosa M, Zen M, Gatto M, et al. IL-12 and IL-23\/Th17 axis in systemic lupus erythematosus. Exp Biol Med (Maywood). 2019;244:42\u201351.","journal-title":"Exp Biol Med (Maywood)"},{"key":"3299_CR52","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12865-015-0070-7","volume":"16","author":"A Zickert","year":"2015","unstructured":"Zickert A, Amoudruz P, Sundstrom Y, Ronnelid J, Malmstrom V, Gunnarsson I. IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment. BMC Immunol. 2015;16:7.","journal-title":"BMC Immunol"},{"key":"3299_CR53","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88:29\u201339.","journal-title":"J Am Acad Dermatol"},{"key":"3299_CR54","doi-asserted-by":"publisher","DOI":"10.25251\/skin.8.supp.419","volume":"8","author":"NJ Korman","year":"2024","unstructured":"Korman NJ, Passeron T, Okubo Y, et al. Deucravacitinib in plaque psoriasis: laboratory parameters through 4 years of treatment in the phase 3 POETYK PSO-1, PSO-2, and LTE trials. J of Skin. 2024;8: s419.","journal-title":"J of Skin"},{"key":"3299_CR55","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.semarthrit.2015.05.009","volume":"45","author":"L Carli","year":"2015","unstructured":"Carli L, Tani C, Vagnani S, Signorini V, Mosca M. Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: prevalence and clinical impact\u2013a systematic literature review. Semin Arthritis Rheum. 2015;45:190\u20134.","journal-title":"Semin Arthritis Rheum"},{"key":"3299_CR56","doi-asserted-by":"publisher","first-page":"5185","DOI":"10.1093\/rheumatology\/keab217","volume":"60","author":"R Kandane-Rathnayake","year":"2021","unstructured":"Kandane-Rathnayake R, Louthrenoo W, Golder V, et al. Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study. Rheumatology (Oxford). 2021;60:5185\u201393.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03299-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03299-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03299-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:02:37Z","timestamp":1762030957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03299-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3299"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03299-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Cristina Arriens received grants, advisory fees, and\/or speaker honoraria from AstraZeneca, Aurinia, Bristol Myers Squibb, Cabaletta, GSK, Health & Wellness Partners, Kezar, Synthekine, and UCB. Eric F. Morand received consulting fees and\/or research support from AbbVie, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Dragonfly, Eli Lilly, EMD Serono, Genentech, Gilead, GSK, Janssen, Novartis, RemeGen, Takeda, UCB, and Zenas. Anca D. Askanase received investigator and consultancy fees from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Celgene, Eli Lilly, Genentech, GSK, Idorsia, Janssen, Pfizer, and UCB. Richard Furie received grant support and consulting fees from Bristol Myers Squibb. Ronald F. van Vollenhoven received research support, educational program support, consultancy, and\/or speaker fees from AbbVie, AstraZeneca, Biogen, Biotest, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Pfizer, Roche, Servier, and UCB. Yoshiya Tanaka received research grants, speaking fees, and\/or honoraria from AbbVie, Eisai, Chugai, Eli Lilly, Boehringer Ingelheim, GSK, Taisho, AstraZeneca, Daiichi Sankyo, Gilead, Pfizer, UCB, Asahi Kasei, and Astellas. Kevin Connors, Monica Davey, Kimberly Young, Richard Meier, Vaishali Shah, and Carolina Leite de Oliveira are employees and shareholders of Bristol Myers Squibb. Giovanni Franchin was an employee and shareholder of Bristol Myers Squibb at the time of manuscript development and is currently an employee of Novartis Pharmaceuticals Corporation. Coburn Hobar was an employee and shareholder of Bristol Myers Squibb at the time of manuscript development. The funding sponsors were involved in the choice of research project; the design of the study; the collection, analyses, and interpretation of data; the writing of the manuscript; and in the decision to publish the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All patients must provide informed consent, and the protocols (code IM011246 and IM011247 on August 12, 2022) must receive approval from the IRB\/IEC associated with each site. Investigators must have IRB\/IEC approval of informed consent forms and other study documents as required, obtain a signed and dated consent form, and revise the consent form if any new information that is relevant to participation arises. Both studies will be conducted in accordance with international guidelines, including the Declaration of Helsinki and Council for International Organizations of Medical Sciences and applicable International Council for Harmonisation Good Clinical Practice guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}